share_log

康方生物:自願公告 - 國家藥品監督管理局受理康方生物自主研發的依若奇單抗注射液(IL-12 / IL-23單克隆抗體,AK101)的新藥上市申請

AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR THE EBDAROKIMAB INJECTION (IL-12/IL-23 MONOCLONAL ANTIBODY, AK101) INDEPENDENTLY-DEVELOPED BY AKESO

香港交易所 ·  Aug 23, 2023 20:29
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more